TECH * logo

Bio-Techne BMV:TECH * Stock Report

Last Price

Mex$1.39k

Market Cap

Mex$213.9b

7D

0%

1Y

-16.4%

Updated

13 Jun, 2023

Data

Company Financials +

Bio-Techne Corporation

BMV:TECH * Stock Report

Market Cap: Mex$213.9b

TECH * Stock Overview

Develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. More details

TECH * fundamental analysis
Snowflake Score
Valuation0/6
Future Growth1/6
Past Performance5/6
Financial Health6/6
Dividends0/6

Rewards

Revenue is forecast to grow 10.87% per year

Earnings grew by 20.3% over the past year

Risk Analysis

Shares are highly illiquid


My Notes

Capture your thoughts, links and company narrative

Bio-Techne Corporation Competitors

Medpace Holdings

NasdaqGS:MEDP

US$10.5b

ICON

NasdaqGS:ICLR

US$17.1b

WuXi Biologics (Cayman)

SEHK:2269

HK$69.9b

Bruker

NasdaqGS:BRKR

US$8.6b

Price History & Performance

Summary of share price highs, lows and changes for Bio-Techne
Historical stock prices
Current Share PriceUS$1,389.66
52 Week HighUS$0
52 Week LowUS$0
Beta1.26
1 Month Change0%
3 Month Change0.52%
1 Year Change-16.37%
3 Year Changen/a
5 Year Changen/a
Change since IPO-45.99%

Recent News & Updates

Recent updates

Shareholder Returns

TECH *MX Life SciencesMX Market
7D0%0%0%
1Y-16.4%0%0%

Return vs Industry: TECH * underperformed the MX Life Sciences industry which returned -14.6% over the past year.

Return vs Market: TECH * underperformed the MX Market which returned 3.7% over the past year.

Price Volatility

Is TECH *'s price volatile compared to industry and market?
TECH * volatility
TECH * Average Weekly Movementn/a
Life Sciences Industry Average Movement0%
Market Average Movement0%
10% most volatile stocks in MX Market0%
10% least volatile stocks in MX Market0%

Stable Share Price: TECH * has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine TECH *'s volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
19763,000Chuck Kummethwww.bio-techne.com

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies.

Bio-Techne Corporation Fundamentals Summary

How do Bio-Techne's earnings and revenue compare to its market cap?
TECH * fundamental statistics
Market capMex$213.92b
Earnings (TTM)Mex$4.69b
Revenue (TTM)Mex$19.41b

45.7x

P/E Ratio

11.0x

P/S Ratio

Is TECH * overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
TECH * income statement (TTM)
RevenueUS$1.12b
Cost of RevenueUS$357.74m
Gross ProfitUS$765.87m
Other ExpensesUS$494.64m
EarningsUS$271.23m

Last Reported Earnings

Mar 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)1.72
Gross Margin68.16%
Net Profit Margin24.14%
Debt/Equity Ratio19.6%

How did TECH * perform over the long term?

See historical performance and comparison

Dividends

0.4%

Current Dividend Yield

19%

Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/06/13 14:29
End of Day Share Price 2023/03/16 00:00
Earnings2023/03/31
Annual Earnings2022/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Bio-Techne Corporation is covered by 27 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David ToungArgus Research Company
James Francis MainwaringAtlantic Equities LLP
Catherine Ramsey SchulteBaird